Shares rose 5% for Novo Nordisk on the approval of oral Wegovy as it looks to ease market pressures with a significant ...
In 2026, J&J expects accelerated growth in the Innovative Medicine segment to be driven by its key products as well as new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback